Teva price target raised to $15 from $14 at BofA

BofA raised the firm’s price target on Teva to $15 from $14 and keeps a Buy rating on the shares. The firm, which forecasts Q4 sales and EBITDA that are slightly higher and roughly in-line versus consensus, respectively, cites a valuation multiple re-rate for its higher target.